Qingdao Vland Biotech INC. (SHA:603739)
15.64
+0.01 (0.06%)
At close: Feb 13, 2026
SHA:603739 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,352 | 1,282 | 1,177 | 1,135 | 1,110 | 936.23 |
Other Revenue | 38.97 | 38.97 | 21.48 | 28.42 | 40.48 | 24.02 |
| 1,391 | 1,321 | 1,199 | 1,163 | 1,151 | 960.25 | |
Revenue Growth (YoY) | 9.97% | 10.16% | 3.07% | 1.07% | 19.85% | 13.40% |
Cost of Revenue | 764.87 | 728.42 | 648.46 | 662.86 | 620.4 | 495.66 |
Gross Profit | 626.07 | 592.34 | 550.44 | 500.3 | 530.43 | 464.59 |
Selling, General & Admin | 355.68 | 343.98 | 314.46 | 297.58 | 285 | 257.92 |
Research & Development | 137.16 | 118.22 | 110.68 | 102.4 | 100.94 | 79.91 |
Other Operating Expenses | 8.91 | 11.79 | 9.19 | 8.78 | 8.96 | 8.67 |
Operating Expenses | 510.37 | 477.91 | 447.32 | 420.62 | 400.69 | 352.79 |
Operating Income | 115.7 | 114.44 | 103.12 | 79.68 | 129.74 | 111.79 |
Interest Expense | -20.97 | -21.88 | -15.22 | -7.17 | -2.12 | -1.78 |
Interest & Investment Income | - | 1.53 | 8 | 3.93 | 7.91 | 6.09 |
Currency Exchange Gain (Loss) | 0.47 | 0.47 | 0.58 | 3.21 | -1.18 | -2.3 |
Other Non Operating Income (Expenses) | -3.41 | -2.97 | -1.62 | -8.46 | -1.88 | -0.45 |
EBT Excluding Unusual Items | 91.78 | 91.58 | 94.87 | 71.18 | 132.46 | 113.35 |
Gain (Loss) on Sale of Investments | 33.82 | 7.08 | 9.22 | 0.21 | 0.43 | 0.45 |
Gain (Loss) on Sale of Assets | -0.04 | 0.13 | -0.25 | 0.29 | -0.05 | 0.14 |
Asset Writedown | 0.27 | -0.07 | -2.75 | - | - | -0.68 |
Other Unusual Items | 23.56 | 24.73 | 21.41 | 30.51 | 38.56 | 26.88 |
Pretax Income | 149.39 | 123.44 | 122.5 | 102.19 | 171.4 | 140.15 |
Income Tax Expense | 35.36 | 31.27 | 19.64 | 16.78 | 21.31 | 17.84 |
Earnings From Continuing Operations | 114.03 | 92.17 | 102.86 | 85.41 | 150.1 | 122.3 |
Minority Interest in Earnings | -30.46 | -29.53 | -22.15 | -15.57 | -17.52 | -13.33 |
Net Income | 83.57 | 62.64 | 80.71 | 69.84 | 132.57 | 108.98 |
Net Income to Common | 83.57 | 62.64 | 80.71 | 69.84 | 132.57 | 108.98 |
Net Income Growth | 26.18% | -22.39% | 15.56% | -47.32% | 21.65% | 40.16% |
Shares Outstanding (Basic) | 252 | 251 | 252 | 249 | 246 | 227 |
Shares Outstanding (Diluted) | 252 | 251 | 252 | 259 | 246 | 227 |
Shares Change (YoY) | -1.15% | -0.66% | -2.50% | 5.36% | 8.14% | 6.37% |
EPS (Basic) | 0.33 | 0.25 | 0.32 | 0.28 | 0.54 | 0.48 |
EPS (Diluted) | 0.33 | 0.25 | 0.32 | 0.27 | 0.54 | 0.48 |
EPS Growth | 27.65% | -21.88% | 18.52% | -50.00% | 12.50% | 31.76% |
Free Cash Flow | 80.51 | 90.69 | -62.05 | -246.72 | -404.06 | -38.83 |
Free Cash Flow Per Share | 0.32 | 0.36 | -0.25 | -0.95 | -1.65 | -0.17 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.160 | 0.143 |
Dividend Growth | - | - | - | -37.50% | 11.97% | - |
Gross Margin | 45.01% | 44.85% | 45.91% | 43.01% | 46.09% | 48.38% |
Operating Margin | 8.32% | 8.66% | 8.60% | 6.85% | 11.27% | 11.64% |
Profit Margin | 6.01% | 4.74% | 6.73% | 6.00% | 11.52% | 11.35% |
Free Cash Flow Margin | 5.79% | 6.87% | -5.18% | -21.21% | -35.11% | -4.04% |
EBITDA | 253.58 | 224.85 | 176.92 | 145.39 | 181.44 | 154.66 |
EBITDA Margin | 18.23% | 17.02% | 14.76% | 12.50% | 15.77% | 16.11% |
D&A For EBITDA | 137.88 | 110.41 | 73.79 | 65.71 | 51.7 | 42.87 |
EBIT | 115.7 | 114.44 | 103.12 | 79.68 | 129.74 | 111.79 |
EBIT Margin | 8.32% | 8.66% | 8.60% | 6.85% | 11.27% | 11.64% |
Effective Tax Rate | 23.67% | 25.33% | 16.03% | 16.42% | 12.43% | 12.73% |
Revenue as Reported | 1,391 | 1,321 | 1,199 | 1,163 | 1,151 | 960.25 |
Advertising Expenses | - | 7.09 | 6.59 | 5.02 | 5.67 | 5.43 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.